Investigating how protein-nanoparticle interactions affect communication in ovarian tumors
Protein-nanoparticle interaction to study multicellular crosstalk within ovarian tumor microenviroment
This study is looking at how tiny gold particles can help us understand how cells in ovarian tumors talk to each other, with the hope of finding better ways to treat ovarian cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11029951 on NIH RePORTER |
What this research studies
This research explores the interactions between proteins and nanoparticles to understand how different cells communicate within the ovarian tumor microenvironment. By using gold nanoparticles, which have shown potential anti-cancer properties, the study aims to uncover the mechanisms behind tumor growth and resistance to treatment. The approach involves using patient-derived models to simulate the tumor environment and observe how these nanoparticles can disrupt harmful cellular interactions. This could lead to new insights into ovarian cancer treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ovarian cancer who are seeking new treatment options.
Not a fit: Patients with non-ovarian cancers or those who are not currently undergoing treatment for ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that improve outcomes for patients with ovarian cancer.
How similar studies have performed: Previous research has shown promise in using nanoparticles for cancer treatment, indicating that this approach could be a valuable addition to existing therapies.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Mukherjee, Priyabrata — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Mukherjee, Priyabrata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.